Healthcare Services

Diabetic Gastroparesis Treatment Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Diabetic Gastroparesis Treatment Market During The Forecast Period 2026–2030?

The diabetic gastroparesis treatment market has experienced robust expansion in recent years. This sector is forecast to expand from $4.05 billion in 2025 to $4.28 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. Historically, this growth has been influenced by factors such as the increasing prevalence of diabetes complications, the limited array of past treatment solutions, enhanced diagnosis rates, a primary focus on pharmacological management, and the evolution of specialized gastroenterology care.

The diabetic gastroparesis treatment market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $5.47 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is attributable to the development of novel prokinetic agents, heightened disease awareness, the proliferation of specialty clinics, the demand for sustained symptom control, and innovation in gastric stimulation technologies. Prominent trends for the forecast period encompass the increasing deployment of prokinetic drug therapies, a rising focus on symptom-based disease management, the broadening of combination pharmacological treatments, the growing adoption of minimally invasive interventions, and an increased emphasis on dietary and lifestyle management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12580&type=smp

Which Major Factors Are Driving The Expansion Of The Diabetic Gastroparesis Treatment Market?

The expansion of the diabetic gastroparesis treatment market is anticipated to be driven by the growing prevalence of diabetes. Diabetes prevalence indicates the percentage of individuals within a population identified with the condition at a particular moment. Treatments for diabetic gastroparesis primarily focus on alleviating symptoms and managing complications of this frequent diabetes-related issue. As an illustration, the International Diabetes Federation, a Belgium-based global not-for-profit entity representing national diabetes associations, reported in April 2025 that approximately 589 million adults between 20 and 79 years old globally had diabetes, with forecasts indicating this figure will climb to 853 million by 2050. Consequently, the rising occurrence of diabetes is propelling the expansion of the diabetic gastroparesis treatment market.

What Market Segments Are Evaluated Within The Diabetic Gastroparesis Treatment Market?

The diabetic gastroparesis treatment market covered in this report is segmented –

1) By Treatment: Medication, Surgery

2) By Route Of Administration: Oral, Injectables

3) By Indication: Compensated Gastroparesis, Gastric Failure

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants

2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage

How Are Trends Shaping The Direction Of The Diabetic Gastroparesis Treatment Market?

Leading firms within the diabetic gastroparesis treatment market are developing sophisticated options, including small bowel intubation, to improve both diagnostic precision and the efficacy of treatments. This procedure, small bowel intubation, entails placing a tube into the small intestine, which facilitates more accurate monitoring and effective therapeutic actions for conditions such as diabetic gastroparesis, characterized by compromised gastric motility. An example of this advancement is seen in September 2024, when Avenacy, a US-based pharmaceutical company, introduced Metoclopramide Injection (USP) in the Unites States. Metoclopramide Injection (USP) is an injectable drug formulated for various purposes, particularly for alleviating symptoms linked to diabetic gastroparesis. It also aids in preventing nausea and vomiting caused by chemotherapy and surgical procedures. Furthermore, this injection assists in small bowel intubation when standard techniques are unsuccessful in guiding a tube past the pylorus. Additionally, it is employed to stimulate gastric emptying and facilitate the movement of barium during radiological examinations.

Who Are The Top Market Participants Influencing The Diabetic Gastroparesis Treatment Market?

Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC

Read the full diabetic gastroparesis treatment market report here:

https://www.thebusinessresearchcompany.com/report/diabetic-gastroparesis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Diabetic Gastroparesis Treatment Market?

North America was the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diabetic Gastroparesis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12580&type=smp

Browse Through More Reports Similar to the Global Diabetic Gastroparesis Treatment Market 2026, By The Business Research Company

Gastroparesis Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Gastroparesis Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Diabetic Foot Ulcer Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795